Jacqueline Barrientos - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jacqueline Barrientos

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

The Lancet. Oncology|January 17, 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.

Blood|December 2, 2016

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

The Lancet. Oncology|January 17, 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.

Blood|December 2, 2016

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.

Pageof 3